| abstract |
The present invention provides TCRs having an affinity (K D ) of less than or equal to 1µM, and/or an off-rate (k off ) of 1x10 -3 S -1 or slower, for the SLYNTVATL-HLA-A*0201 complex PROVIDED THAT when the said TCR is presented by cell and comprises SEQ ID NOs: 1 and 2, the cell is not a native T cell. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting HIV infected cells presenting that complex. |